A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Summary

CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.

Timeline

Start

2021-10-29

Primary completion

2026-03

Completion

2026-06

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

release “Data demonstrate monotherapy anti-tumor activity of CLN-619, including objective tumor responses, across multiple tumor types” cullinantherapeutics.com ↗

release “Confirmed partial responses (PR) were observed in 3 patients treated with CLN-619 at doses ≥3mg/kg in combination with pembrolizumab.” cullinantherapeutics.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CLN-619	Monoclonal antibody	—	—
Subject	Datopotamab deruxtecan	Monoclonal antibody	—	—
Subject	Pembrolizumab	Monoclonal antibody	—	—
Background	Carboplatin	Small molecule	—	—
Background	Paclitaxel	Small molecule	—	—
Background	Pemetrexed	Small molecule	—	—

Indications